Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...
Drug
Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu
Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...
Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a Chinese pharmaceutical company, has announced the submission of...
Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial
Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...
Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Sichuan Huiyu Pharmaceutical’s HYP-6589 Receives NMPA Approval for Solid Tumor Clinical Trial
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
Ascentage Pharma’s Lisaftoclax and AceLink Therapeutics’ AL01211 Receive FDA Designations
The Center for Drug Evaluation (CDE) website has indicated that China-based Ascentage Pharma’s (HKG: 6855)...
AskBio’s AB-1003 Receives Rare Pediatric Disease and Orphan Drug Designations from FDA
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned subsidiary of Bayer AG (ETR: BAYN), has announced...
CDE Releases Technical Guidelines for Pilot Registration and Phased Manufacturing of ADCs
The Center for Drug Evaluation (CDE) has issued the “Technical Requirements for Pilot Registration and...
Belief BioMed’s BBM-D101 Receives FDA Orphan Drug and Pediatric Rare Disease Designations for DMD
Belief BioMed has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...
HutchMed to Present Updated Data from Solvleplenib ESLIM-01 Phase III Trial at ASH and ESMO Congress 2024
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced plans to present new and...
Pfizer’s Talzenna (talazoparib) Approved by China’s NMPA for mCRPC Treatment
The National Medical Products Administration (NMPA) website has indicated that Pfizer’s (NYSE: PFE) marketing filing...
Shouyao Holdings Adjusts Development Strategy for SY-1530, Halts Monotherapy Clinical Trials
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced a strategic adjustment regarding its...
Nanjing Leads Biolabs Secures FDA Orphan Drug Designation for LBL-034 in Multiple Myeloma Treatment
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced that it has received...
Sanofi’s Dupixent Gains EMA Approval for Eosinophilic Esophagitis in Children
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...
China’s NHC Announces Initiative to Boost Gerontology Medical Services
The National Health Commission (NHC) has issued a notification aimed at enhancing gerontology medical service...
Amgen’s Tavneos Receives NMPA Approval for ANCA-Associated Vasculitis Treatment in China
US biotechnology company Amgen (NASDAQ: AMGN) has announced that it has received market approval in...
CARSgen Therapeutics Presents Latest CAR-T Data at ASH Annual Meeting
CARSgen Therapeutics Holdings Ltd (HKG: 2171), a China-based specialist in chimeric antigen receptor (CAR)-T cell...
Changchun High & New Technology Industries Receives NMPA Approval for Long-Acting Somatropin
Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading China-based company, has...
Huadong Medicine Co., Ltd Receives NMPA Approval for Stelara Biosimilar SaiLeXin
Huadong Medicine Co., Ltd (SHE: 000963), a China-based pharmaceutical company, has announced that it has...